Lupin will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live News

Lupin today announced that it has received the highest `A` leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition affirms Lupin`s position among distinguished global leaders who champion sustainability and transparency at the highest level. Lupin`s double `A` rating in Climate and Water exemplifies its steadfast commitment to sustainability and proactive initiatives aimed at mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. This represents a substantial enhancement compared to Lupin`s 2024 ratings of `A-` in both categories, as well as the ratings of `B` in 2023 for climate and `C` for water, thereby reflecting significant year-over-year progress. Lupin has not only received recognition from CDP but also achieved an S&P Global ESG score of 91 in 2025. This is a best-in-class global achievement, positioning Lupin among a distinguished group of companies worldwide that have surpassed the 90-point threshold. Powered by Capital Market - Live News

Lupin announced a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings SA (LAHSA) with Galenicum Health, S.L.U. (Galenicum) for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia and Latin America. Lupin is well-positioned to expand its leadership in diabetes care and obesity beyond India with this Semaglutide partnership.Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar and appetite. It is mainly prescribed for adults with Type 2 Diabetes, alongside diet and exercise, and is also used for long-term weight management in adults with obesity or overweight conditions. Powered by Capital Market - Live News

Lupin has entered into an exclusive License, Supply and Distribution agreement with Gan & Lee Pharmaceuticals, headquartered in China, for a novel fortnightly GLP-1 receptor agonist, Bofanglutide. The agreement strengthens Lupin`s diabetes portfolio and accelerates its presence in the obesity segment. Bofanglutide injection is a fortnightly (once in two weeks) GLP-1 receptor agonist developed by Gan & Lee, intended for treating adults with type 2 diabetes and aiding weight management in overweight or obese individuals. As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that the weight loss results of Bofanglutide are comparable to or better than those of existing GLP-1 alternatives while offering the convenience of once in two weeks versus once a week for other injectable alternatives, and maintaining safety and tolerability consistent with the GLP-1 class. It effectively reduces both blood glucose levels and body weight.Obesity is anticipated to develop into a significant health crisis in India, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes is already considered an epidemic, with approximately 90 million adults affected by the condition. Under the terms of the agreement, Lupin will have exclusive rights to commercialize and distribute Bofanglutide in India. Powered by Capital Market - Live News

Lupin announced that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These validations cover all three emission scopes �V Scope 1, Scope 2, and Scope 3 - aligning with the Paris Agreement to limit global temperature rise to 1.5�XC. This milestone underscores Lupin��s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets. Key short-term targets: �h - Reduce absolute Scope 1 and 2 greenhouse gas emissions by 42.0% by FY 2030, with FY 2023 as the base year. �h - Reduce Scope 3 greenhouse gas emissions by 61.07% by FY 2033, across purchased goods and services, fuel- and energy-related activities, upstream and downstream transportation and distribution, business travel, employee commuting, processing and use of sold products, and franchises, using FY 2024 as the baseline.These goals are aligned with the 1.5�XC pathway and validated under SBTi��s latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change. Powered by Capital Market - Live News